Endovastec(SH:688016) Sou Hu Cai Jing·2025-04-06 17:53Summary of Key Points Core Viewpoint - The company, Xinmai Medical, is actively engaging in share repurchase programs and preparing for its annual shareholder meeting, indicating a focus on shareholder value and financial performance. Trading Information - On April 3, 2025, Xinmai Medical's stock closed at 97.52 yuan, down 0.88%, with a turnover rate of 2.74% and a trading volume of 33,800 shares, amounting to a total transaction value of 331 million yuan [1]. - The net outflow of main funds was 34.22 million yuan, accounting for 10.33% of the total transaction value, while retail investors saw a net inflow of 14.63 million yuan, representing 4.42% of the total [2]. Company Announcements - Xinmai Medical has repurchased a total of 864,989 shares, with a total expenditure of 91,560,636.42 yuan, intended for employee stock ownership plans or equity incentives [2]. - The company will hold its 2024 annual shareholder meeting on April 18, 2025, to discuss nine agenda items, including the annual report, financial statements, and profit distribution proposals [2][3]. Share Repurchase Program - The initial disclosure of the repurchase plan was on October 30, 2024, with a buyback period from October 28, 2024, to October 27, 2025, and an expected repurchase amount between 100 million yuan and 200 million yuan [3]. - As of March 31, 2025, the repurchased shares accounted for 0.70% of the total share capital, with a repurchase price range between 93.10 yuan and 119.82 yuan per share [3]. - The maximum repurchase price was adjusted to 178.35 yuan per share due to the implementation of the 2024 interim profit distribution [3]. Financial Performance - In 2024, Xinmai Medical reported a revenue of 1.206 billion yuan and a net profit attributable to the parent company of 502 million yuan [3]. - The company plans to distribute a cash dividend of 3.5 yuan per 10 shares (including tax), totaling 42.4585 million yuan, and anticipates a mid-2025 profit distribution not exceeding the net profit for the corresponding period [3].